79329052 - PIONEER

Information

  • Trademark
  • 79329052
  • Serial Number
    79329052
  • Registration Number
    7021191
  • Filing Date
    October 06, 2021
    2 years ago
  • Registration Date
    April 11, 2023
    a year ago
  • Transaction Date
    August 14, 2023
    9 months ago
  • Status Date
    April 11, 2023
    a year ago
  • Published for Opposition Date
    January 24, 2023
    a year ago
  • Location Date
    April 11, 2023
    a year ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    MALYSZEK, KIMBERLY RAY
  • Attorney Docket Number
    1269445
    Attorney Name
    Margaret C. McHugh
    Law Office Assigned Location Code
    O30
  • Owners
Mark Drawing Code
4000
Mark Identification
PIONEER
Case File Statements
  • GS0401: Antibody production for others, and manufacture of antibodies for others; custom manufacture of antibodies, namely, antibody purification, antibody fragmentation; custom production of cell cultures and biological products in the nature of antibodies and proteins and related reagents; custom antibody production; custom manufacturing for others, namely, manufacturing of chemical and biotechnological materials for others, namely, manufacturing of organisms, compounds and materials for use in the pharmaceutical, agrochemical, chemical, biotechnology industries
  • GS0051: Biological preparations for the treatment of infectious diseases, deficiency diseases, hereditary diseases, and physiological diseases; pharmaceutical, biopharmaceutical and medical preparations for the treatment of infectious diseases, deficiency diseases, hereditary diseases, and physiological diseases; diagnostic preparations for medical purposes; antibodies for medical purposes; biological preparations, namely, immunoglobulins, antibodies, or fragments thereof, for medical use; antibody libraries, for medical and veterinary use, namely, collections of antibodies for medical purposes; libraries of immunoglobulins, antibodies, or fragments thereof, for medical use, namely, collections of biological preparations in the nature of immunoglobulins, antibodies, or fragments thereof, for medical use, sold as a unit; biological preparations comprised of immunoglobulins, antibodies, or fragments thereof, for use in medicine; diagnostic reagents for medical purposes; diagnostic reagents for medical use; diagnostic reagents for medical clinician or medical use
  • GS0011: Chemicals for use in industry and science, namely, diagnostic kits consisting primarily of antibodies and reagents for use in disease testing; biological preparations in the nature of antibodies for research use, other than for medical or veterinary purposes; antibody libraries, for scientific, industrial or research use, namely, biological preparations in the nature of antibodies sold together; libraries of immunoglobulins, antibodies, or fragments thereof, for scientific, industrial, and research use, namely, biological preparations in the nature of immunoglobulins, antibodies, or fragments thereof sold together as a kit; biological preparations in the nature of immunoglobulins, antibodies, or fragments thereof, for scientific, industrial, and research use; assays and reagents for use in genetic research; diagnostic reagents for scientific and research use; reagents and kits comprising chemical reagents, both for scientific or research use in the field of diagnosing diseases
  • GS0421: Research and development in the field of antibody generation services; medical and scientific research for the identification, preparation, and development of antibody libraries; Chemical, biochemical, biological and bacteriological research and analysis services in the nature of preparation and screening of libraries of proteins and antibodies, libraries of cells producing antibodies and proteins, and libraries of vector coding for antibodies and proteins; design of antibody libraries for medical or veterinary use; scientific and technological services, namely, scientific and technological research, analysis, inspection, quality audit, consulting, design, engineering, development and laboratory testing services for others; research and development services in the field of developing new chemicals; testing or scientific research on biotechnology and providing scientific information and research consultancy relating thereto; providing information and consultancy on testing, inspection or research of pharmaceuticals, chemicals for use in medicines, reagents for use in medicines, cosmetics or foodstuffs; scientific or laboratory testing, inspection or research of nucleic acids, chemicals and pharmaceuticals for drug development and medical research purposes, and providing scientific information and research consultancy relating thereto; genomic experiments, analyses, research, assays, tests, inspection, detection or verification, namely, scientific laboratory services being scientific genomic analyses, scientific genomic research, custom design and development of biochemical genomic assays, genome amplification and functional and structural analysis of genomes; scientific laboratory services of a chemist, biologist, biochemist, biotechnologists, gene technologists, molecular biologists, pharmacists, protein chemist; chemical and biological analysis and research services; pharmaceutical, medical, scientific and biopharmaceutical research and development; drug discovery services; research relating to medicines; research and development of medicines; development of pharmaceutical and biopharmaceutical preparations and medicines
Case File Event Statements
  • 8/14/2023 - 9 months ago
    30 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 7/26/2023 - 10 months ago
    29 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 7/26/2023 - 10 months ago
    28 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 7/11/2023 - 10 months ago
    27 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 4/11/2023 - a year ago
    26 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 4/11/2023 - a year ago
    25 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 1/24/2023 - a year ago
    24 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 1/24/2023 - a year ago
    23 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 1/24/2023 - a year ago
    22 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/4/2023 - a year ago
    21 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 1/4/2023 - a year ago
    20 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 1/4/2023 - a year ago
    19 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 12/20/2022 - a year ago
    18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 12/20/2022 - a year ago
    17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 12/20/2022 - a year ago
    16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 12/20/2022 - a year ago
    15 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 12/20/2022 - a year ago
    14 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 12/14/2022 - a year ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/14/2022 - a year ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/14/2022 - a year ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 7/19/2022 - a year ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 6/25/2022 - a year ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 6/25/2022 - a year ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 6/17/2022 - a year ago
    7 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 6/16/2022 - a year ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 6/15/2022 - a year ago
    5 - ASSIGNED TO EXAMINER Type: DOCK
  • 6/3/2022 - 2 years ago
    4 - CHANGE OF OWNER RECEIVED FROM IB Type: CHLD
  • 1/4/2022 - 2 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 12/29/2021 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 12/23/2021 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR